10.0 Abstract: Experimental Therapeutics (ET) Program The overarching goal of ET is to develop and test new therapies for solid tumors and hematologic malignancies based on innovative preclinical research. The emphasis is on bringing basic and preclinical discoveries from ET members to early-stage clinical testing and also on providing platforms for investigators in other programs to evaluate their findings in clinical settings. To achieve this mission, the program focuses on three specific aims: Aim 1: Target detection and measurement—Investigate diagnostic advances, including molecular early detection, liquid biopsy and imaging, to guide new treatment approaches and assessments of response; Aim 2: Molecular targeting: Development and preclinical and clinical testing—Investigate new cancer therapies based on novel molecular targets in in vitro and in vivo laboratory studies as well as early phase clinical trials; and Aim 3: Treatment delivery: Novel delivery strategies—Investigate the development of new technologies for therapy delivery, including molecular carriers, nanotechnology, and novel radiation therapy and radiation protection approaches. To achieve these three aims, members of ET are supported by extensive expertise available in other University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center (UMGCCC) Programs to translate basic research findings to the clinic and by the availability of exceptional shared services. The ET Program has 56 members, including 31 full members and 25 associate members, who conduct cancer-focused research that receives $14.6 million direct cost annual funding ($19.4 million total), including $3.6 million (25%) from NCI and $4.1 million from other peer-reviewed sources. ET Program members receive $6.9 million annually from non-peer-reviewed funding sources. During this funding period, ET members authored 889 cancer-related publications, of which 22% resulted from intraprogrammatic, 21% from interprogrammatic, and 8% from intra- and interprogrammatic collaborations. Of the 889 publications, 72% include collaborations with external investigators, reflecting the high national impact of the ET Program. A high percentage of ET publications (14%) were in journals with an impact factor ≥10. Research efforts of ET members are supported by extensive use of all shared services. The ET Program collaborates with the other four UMGCCC research programs and facilitate community outreach and engagement (COE) to identify and address the cancer research priorities of the catchment area.